Fig. 1

CDX2 is poorly expressed in breast cancer, and overexpression of CDX2 suppresses migration and invasion of breast cancer epithelial cells. a CDX2 mRNA expression detected by RT-qPCR (n = 86); b immunohistochemical images of CDX2 in breast cancer and adjacent normal tissues (×400); c CDX2 positive rate in tissues measured by Immunohistochemistry (n = 86); d relative expression of CDX2 protein in tissues examined by western blot analysis (n = 86); *p < 0.05 vs. adjacent normal tissues; e CDX2 in breast cancer survival rate analyzed by Kaplan–Meier; f breast cancer cell line with the lowest expression of CDX2 screened by RT-qPCR; *p < 0.05 vs. normal human breast epithelial cell line HBL-100; g CDX2 mRNA expression in MCF-7 cells detected by RT-qPCR after 48-h of transfection; h MCF-7 cell proliferation ability determined by EdU assay after 48-h of transfection (×200); i MCF-7 cell migration ability examined by Transwell migration assay (×200); j MCF-7 cell invasion ability (×200); k CDX2, E-cadherin and Vimentin protein expression in MCF-cells after 48-h of transfection; *p < 0.05 vs. oe-CDX2 NC. Measurement data were described as mean ± standard deviation. Paired t-test was applied for a, c, and d, while unpaired t-test was conducted for f−k analyses. Each cellular experiment was repeated 3 times